Expand ALGS Menu
ALGS MENU

ALGS Latest Press Releases

-- April 30, 2026 --

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 Globe Newswire 4:05 PM

-- April 24, 2026 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- April 16, 2026 --

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Globe Newswire 6:00 AM

-- April 14, 2026 --

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation Globe Newswire 4:05 PM

-- March 5, 2026 --

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 8:00 AM

-- February 26, 2026 --

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 Globe Newswire 8:00 AM

-- February 23, 2026 --

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) Globe Newswire 8:00 AM

-- January 30, 2026 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- January 21, 2026 --

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates Globe Newswire 8:00 AM

-- January 13, 2026 --

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer Globe Newswire 8:00 AM

-- December 12, 2025 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- December 11, 2025 --

Aligos Therapeutics Presents Positive Data at HEP-DART 2025 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes